Berkshire Hathaway liquidated its investment in Teva in the fourth quarter of 2021

Berkshire Hathaway, which is controlled and managed by legendary investor Warren Buffett, liquidated its investment in Teva in the fourth quarter of 2021, according to the company's periodic report on its investments in the US Securities and Exchange Commission website.
Berkshire Hathaway held 42.8 million shares of Teva - which is 3.8% of the company - at the end of the third quarter of 2021. According to the average price of Teva shares in the fourth quarter, Berkshire's consideration from the sale of Teva shares was $ 387 million.
The holding company first invested in Teva in the first quarter of 2018 without Buffett himself's knowledge - as he previously admitted in a media interview. The first investment is estimated at $ 1 billion, probably against the background of the estimate that Kor Schultz's appointment as CEO in November 2017 will pave the way for the company's recovery and the share price recovery, which then reflected a company value of $ 25 billion.
Schultz has come a long way in reducing Teva's financial debt by $ 15 billion, not including interest payments, but the company's legal entanglement in the narcotic painkiller (opioid) case, the suspicion of price coordination in the US generic drug market and the suspicion of providing illegal incentives to patients with the original drug Copaxone For the treatment of multiple sclerosis - Teva shares, which have collapsed by 55% since the acquisition of Berkshire Hathaway.